In-vitro analysis reveals Osteon II and HXT2 excel in osteoconductivity and mineralization in osteoblasts.
Objectives: To investigate the effect of different bone graft substitutes on osteoconduction and mineralization in bone cells derived from the osteoblast cell line hFOB 1.19. Methods: Osteoblast cells were cultured and placed on different bone graft materials, including Bio-Oss (xenograft), M bone (alloplast), Osteon II (alloplast), HXT1, and HXT2 (hybrid between xenograft and TCP). The concentration of elements in bone grafts was analyzed by X-ray fluorescence (XRF). The vitality test was evaluated by the methyl thiazolyl tetrazolium assay (MTT) after 1, 3, and 7 days. Alkaline phosphatase (ALP) activity was measured at 3, 7, and 14 days. Alizarin red S staining assay was performed at 7, 14, 21, and 28 days. The data were analyzed using ANOVA along with Tukey's honestly significant difference test. Results: The cell viability rate was significantly higher in Osteon II and HXT2 compared to the other materials (p<0.001). On day 14, Osteon II and the HXT2 group had higher levels of ALP activity than the Bio-Oss group (p<0.05). Alizarin red assay showed that Osteon II had the highest mineralization (p<0.001) at days 14, 21, and 28, followed by HXT2 and Bio-Oss respectively. Conclusions: Osteon II, an alloplastic bone graft, and HXT2, a newly developed hybrid between xenograft and TCP, exhibited high viability rates and expression levels in mineralized tissue cells of the osteoblast cell line hFOB 1.19 in vitro.
No takes yet. Share an insight, caveat, or question.
Pongpila et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: